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Abstract
Allogeneic hematopoietic stem cell transplantation is a curative therapy for a number of hematological
malignancies, but is limited by the development of graft‐versus‐host disease (GVHD). CD39 and CD73 form
an ectoenzymatic pathway that hydrolyzes extracellular adenosine 5′‐triphosphate (ATP) to adenosine, which
respectively exacerbate or alleviate disease in allogeneic mouse models of GVHD. The current study aimed to
explore the role of the CD39/CD73 pathway and adenosine receptor (AR) blockade in a humanized mouse
model of GVHD. Immunodeficient nonobese diabetic‐severe combined immunodeficiency‐IL‐2 receptor
γnull mice were injected with human peripheral blood mononuclear cells, and subsequently injected with the
CD39/CD73 antagonist αβ‐methylene‐ADP (APCP) (50 mg kg−1) or saline for 7 days, or the AR antagonist
caffeine (10 mg kg−1) or saline for 14 days. Mice predominantly engrafted human CD4+ and CD8+ T cells,
with smaller proportions of human regulatory T cells, invariant natural killer T cells, monocytes and dendritic
cells. Neither APCP nor caffeine altered engraftment of these human leukocyte subsets. APCP (CD39/CD73
blockade) augmented GVHD as shown through increased weight loss and worsened liver histology, including
increased leukocyte and human T‐cell infiltration, and increased apoptosis. This treatment also increased
serum human IL‐2 concentrations and decreased the frequency of human CD39− CD73− CD4+ T cells. In
contrast, caffeine (AR blockade) did not alter GVHD severity or human serum cytokine concentrations
(IL‐2, IL‐6, IL‐10 or tumor necrosis factor‐α). In conclusion, blockade of CD39/CD73 but not ARs
augments disease in a humanized mouse model of GVHD. These results indicate that CD39/CD73 blockade
maintains sufficient extracellular ATP concentrations to promote GVHD in this model.
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ABSTRACT 25 
Allogeneic haematopoietic stem cell transplantation (HSCT) is a curative therapy for a 26 
number of haematological malignancies, but is limited by the development of graft-versus-27 
host disease (GVHD). CD39 and CD73 form an ecto-enzymatic pathway that hydrolyses 28 
extracellular adenosine 5’-triphosphate (ATP) to adenosine, which respectively exacerbate or 29 
alleviate disease in allogeneic mouse models of GVHD. The current study aimed to explore 30 
the role of the CD39/CD73 pathway and adenosine receptor (AR) blockade in a humanised 31 
mouse model of GVHD. Immunodeficient non-obese diabetic-severe combined 32 
immunodeficiency-IL-2 receptor γnull (NSG) mice were injected with human peripheral blood 33 
mononuclear cells (PBMCs), and subsequently injected with the CD39/CD73 antagonist αβ-34 
methylene-ADP (APCP) (50 mg/kg) or saline for 7 days, or the AR antagonist caffeine (10 35 
mg/kg) or saline for 14 days. Mice predominantly engrafted human CD4+ and CD8+ T cells, 36 
with smaller proportions of human regulatory T (Treg) cells, invariant natural killer T (iNKT) 37 
cells, monocytes and dendritic cells (DCs). Neither APCP or caffeine altered engraftment of 38 
these human leukocyte subsets. APCP (CD39/CD73 blockade) augmented GVHD as shown 39 
through increased weight loss and worsened liver histology, including increased leukocyte 40 
and human T cell infiltration, and increased apoptosis. This treatment also increased serum 41 
human IL-2 concentrations and decreased the frequency of human CD39-CD73-CD4+ T cells. 42 
In contrast, caffeine (AR blockade) did not alter GVHD severity or human serum cytokine 43 
concentrations (IL-2, IL-6, IL-10 or TNFα). In conclusion, blockade of CD39/CD73 but not 44 
ARs augments disease in a humanised mouse model of GVHD. These results indicate that 45 
CD39/CD73 blockade maintains sufficient extracellular ATP concentrations to promote 46 
GVHD in this model. 47 
 48 
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INTRODUCTION 49 
Allogeneic haematopoietic stem cell transplantation (HSCT) is a common curative therapy 50 
for numerous haematological malignancies. However, 30-60% of transplant recipients 51 
develop graft-versus-host disease (GVHD) as a result of the donor T cells recognising the 52 
recipient tissue as ‘foreign’1. The first stage of GVHD is characterised by the initial release of 53 
cytokines, such as TNF-α and IL-6, from damaged tissue caused by the underlying disease or 54 
pre-conditioning regimes. Following this, activation of CD4+ T cells by antigen presenting 55 
cells, such as dendritic cells (DC), can cause release of T helper-1 (Th1) cytokines such as 56 
TNF-α, IFN-γ and IL-2. Finally, both CD4+ and CD8+ T cells migrate to the liver, 57 
gastrointestinal tract and skin to cause inflammatory damage of these tissues2. Alternatively, 58 
IL-10 can suppress immune responses and can potentially reduce GVHD3. The T cell subsets 59 
regulatory T (Treg) cells and invariant natural killer T (iNKT) cells can also reduce GVHD 60 
severity4.  61 
Purinergic signalling includes the plasma membrane P1 and P2 receptors. P1 or adenosine 62 
receptors (AR; A1, A2A, A2B and A3) are activated by extracellular adenosine, while P2 63 
receptors (P2X1-7 and P2Y1, 2, 4, 6, 8, 11-14) are activated by a range of extracellular nucleotides 64 
including adenosine 5’-triphosphate (ATP)5. Purinergic receptors are important in 65 
inflammation and immunity, and are expressed on immune cells including antigen presenting 66 
cells and T cells6. In general activation of P2 receptors by extracellular ATP exerts pro-67 
inflammatory effects7 including T cell activation and migration8,9. In contrast, hydrolysis of 68 
ATP to adenosine by a pathway involving ecto-nucleoside triphosphate diphosphohydrolase-69 
1 (CD39) and ecto-5’-nucleotidase (CD73) commonly results in anti-inflammatory effects via 70 
activation of ARs10. 71 
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ATP, released from activated, damaged or dying cells, can activate P2 receptors and promote 72 
inflammatory responses in transplantation11. Moreover, P2 receptor activation can promote 73 
development of GVHD. Extracellular ATP can be released from damaged cells in GVHD12 74 
and subsequently activate P2X7 to promote disease development in allogeneic12-14 and 75 
humanised15,16 mouse models of GVHD. Likewise, P2Y2 activation by ATP can promote 76 
leukocyte infiltration and tissue damage in allogeneic models of GVHD17. In contrast, 77 
activation of ARs can limit GVHD development18,19. Moreover, pharmacological blockade of 78 
ARs with caffeine20 or A2A with SCH5826121 or genetic deletion of A2A20,21 worsens disease 79 
in allogeneic mouse models of GVHD. Similarly, pharmacological blockade of CD39 and 80 
CD73 with αβ-methylene-ADP (APCP), which prevents adenosine generation and increases 81 
extracellular ATP22,23, augments GVHD in allogeneic mouse models21. However, the roles of 82 
the CD39/CD73 pathway and ARs in a humanised mouse model of GVHD have not been 83 
reported.  84 
Using pharmacological approaches, the current study aimed to investigate the role of the 85 
CD39/CD73 pathway and AR blockade in disease development in a humanised mouse model 86 
of GVHD. In this model, immunodeficient non-obese diabetic-severe combined 87 
immunodeficiency-IL-2 receptor γnull (NSG) mice are injected with human peripheral blood 88 
mononuclear cells (PBMC) and develop clinical signs of GVHD over 10 weeks15. 89 
CD39/CD73 blockade with APCP, but not AR blockade with caffeine, augments GVHD in 90 
humanised mice. These results support the known roles of extracellular ATP in promoting 91 
GVHD, but do not provide evidence that extracellular adenosine can limit GVHD in this 92 
humanised model. 93 
 94 
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RESULTS  95 
APCP does not impact hPBMC engraftment in NSG mice 96 
To investigate a role for the CD39/CD73 pathway in GVHD development in humanised NSG 97 
mice, these mice were injected with the CD39/CD73 inhibitor, APCP, using the same regime 98 
efficacious in an allogneic mouse model of GVHD20. First, to investigate whether APCP 99 
(CD39/CD73 blockade) altered hPBMC engraftment in NSG mice, 3 weeks post-hPBMC 100 
injection blood cells from APCP- (n = 9) or saline-injected (n = 9) mice were analysed by 101 
flow cytometry. APCP- and saline-injected mice demonstrated similar frequencies of human 102 
leukocytes (hCD45+mCD45- cells), calculated as a percentage of total leukocytes 103 
(hCD45+mCD45-/(hCD45+mCD45- and hCD45-mCD45+) (22.1 ± 3.9% and 22.2 ± 5.4%, 104 
respectively, P = 0.9869) (Fig 1a). These human leukocytes from APCP- and saline-injected 105 
mice predominately comprised T cells (hCD3+hCD19-) (99.5 ± 0.1% and 99.3 ± 0.3%, 106 
respectively, P = 0.4897) (Fig 1b), with a small amount of non-B/T cells (hCD3- hCD19-)  107 
(0.5 ± 0.1% and 0.7 ± 0.3%, respectively, P = 0.4897) (Fig 1c). 108 
At end-point, splenocytes from APCP- (n = 9) and saline-injected (n = 8) mice were analysed 109 
by flow cytometry. APCP- and saline-injected mice demonstrated similar frequencies of 110 
human leukocytes (75.1 ± 9.4% and 90.2 ± 3.0%, respectively, P = 0.1691) (Fig 1d). One 111 
APCP-injected mouse revealed a human leukocyte frequency of only 9.7% (Fig 1d) but was 112 
included in subsequent analyses. APCP- and saline-injected mice demonstrated similar 113 
frequencies of human T cells (92.5 ± 1.9% and 95.1 ± 1.6%, respectively, P = 0.3128) (Fig 114 
1e), which comprised both hCD4+ T cells (58.3 ± 6.5% and 64.0 ± 7.0%, respectively, P = 115 
0.5558) and hCD8+ T cells (29.6 ± 6.0% and 19.2 ± 3.3%, respectively, P = 0.1633) (Fig 1f). 116 
Both APCP- and saline-injected mice demonstrated greater frequencies of hCD4+ T cells than 117 
hCD8+ T cells (P = 0.0053 and P < 0.0001, respectively) (Fig 1f). 118 
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To investigate whether APCP altered the frequency of CD39+/- and/or CD73+/- human T cells, 119 
these markers on hCD4+ and hCD8+ T cells from the spleens of humanised mice were 120 
analysed by flow cytometry. APCP-injected mice, compared to saline-injected mice, 121 
demonstrated a trend of increased hCD39+hCD73-hCD4+ T cells and hCD39-hCD73+hCD4+ 122 
T cells, but a similar frequency of hCD39+hCD73+hCD4+ T cells (Fig 1g; Table 2). 123 
Conversely, the frequency of hCD39-hCD73-hCD4+ T cells was significantly reduced in 124 
APCP-injected mice compared to saline-injected mice (Table 2). In contrast to hCD4+ T cells, 125 
APCP- and saline-injected mice demonstrated similar frequencies of these respective hCD8+ 126 
T cell subsets (Fig 1h; Table 2). 127 
Previous studies have demonstrated that increased proportions of iNKT and Treg cells 128 
correlate to reduced GVHD severity in allogeneic mouse models of GVHD4, but the presence 129 
of human iNKT cells in humanised NSG mice is unknown. Therefore, the presence and 130 
frequency of human iNKT cells (hCD45+hCD3+hCD19-hVα24-Jα18+), as well as human 131 
Treg cells (hCD45+hCD3+hCD4+hCD25+hCD127lo), in the spleens of these mice was 132 
examined. APCP- and saline-injected mice demonstrated the presence and similar 133 
frequencies of iNKT cells (2.4 ± 1.0% and 1.4 ± 0.4%, respectively, P = 0.3674) (Fig 1i). 134 
APCP- and saline-injected mice also demonstrated similar frequencies of Treg cells (1.4 ± 135 
0.6 and 0.9 ± 0.2%, respectively, P = 0.4983) (Fig 1j). 136 
Previously, our group observed that the spleens of humanised mice at end-point do not 137 
contain human B cells15. Consistent with this observation, the remaining human leukocytes in 138 
the spleens of APCP- and saline-injected mice were negative for CD19, with similar 139 
frequencies of CD3-CD19- cells present in both groups of mice (7.5 ± 1.9% and 3.2 ± 1.0%, 140 
respectively, P = 0.0703) (Fig 1k). Therefore, this remaining non-B/T cell population 141 
(hCD45+hCD3-hCD19-) was further analysed to determine if these cells were human 142 
monocytes (hCD14+hCD83-) or DCs (hCD14-hCD83+). APCP- and saline-injected mice 143 
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demonstrated small but similar frequencies of human monocytes (0.03 ± 0.02% and 0.001 ± 144 
0.001%, respectively, P = 0.1804) (Fig 1l) and human DCs (0.4 ± 0.2% and 0.3 ± 0.1%, 145 
respectively, P = 0.6066) (Fig 1m).  146 
APCP augments clinical and histological GVHD in humanised mice 147 
To investigate whether APCP (CD39/CD73 blockade) impacted GVHD development, the 148 
above mice were monitored for disease development for up to 10 weeks. APCP-injected mice 149 
(n = 9) demonstrated significantly greater weight loss over the 10 weeks than saline-injected 150 
mice (n = 9) (P = 0.0350) (Fig 2a). APCP-mice demonstrated signs of GVHD (classified as a 151 
clinical score ≥ 3)24 from 38 days onwards, while saline-injected mice demonstrated signs of 152 
GVHD from 45 days, however, clinical scores were similar over 10 weeks (P = 0.1711) (Fig 153 
2b). Moreover, APCP- and saline-injected mice exhibited identical median survival times 154 
(MST) (57 days and 57 days, respectively, P = 0.2634) and similar mortality over 10 weeks 155 
(100% and 78%, respectively, P = 0.2059) (Fig 2c). 156 
GVHD affects the liver, gastrointestinal tract and skin in humans25, and in allogeneic26 and 157 
humanised27 mouse models. APCP-injected mice exhibited greater histological damage and 158 
leukocyte infiltration into the liver (1052.0 ± 110.0 cells field of view-1, n = 9) compared to 159 
saline-injected mice (727.8 ± 98.0 cells field of view-1, n = 9) (P = 0.0216) (Fig 3a-b). In 160 
contrast, the small intestines of APCP- and saline-injected mice exhibited similar amounts of 161 
leukocyte infiltration (234.7 ± 46.6 cells field of view-1, n = 9 and 196.4 ± 34.1 cells field of 162 
view-1, n = 9, respectively, P = 0.5179), crypt epithelial cell apoptosis and structural damage 163 
including rounding of villi (Fig 3a-b). Similarly, the skin of APCP- and saline-injected mice 164 
displayed similar amounts of leukocyte infiltration (512.8 ± 64.5 cells field of view-1, n = 9 165 
and 617.8 ± 78.1 cells field of view-1, n = 9, respectively, P = 0.3127), with similar but 166 
minimal amounts of basal epithelial cell apoptosis and epidermal thickening (Fig 3a-b). 167 
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Livers from APCP-injected mice demonstrated significantly increased human T cell 168 
infiltration (62.0 ± 12.1 cells field of view-1, n = 4) compared to saline-injected mice (31.4 ± 169 
4.4 cells field of view-1, n = 4) (P = 0.0271) (Fig 3c-d). Livers from APCP-injected mice also 170 
demonstrated increased apoptotic cells (270 ± 62.5 cells field of view-1, n = 4) compared to 171 
saline-injected mice (126.1 ± 10.7 cells field of view-1, n = 4) (P = 0.0319) (Fig 3e-f). Similar 172 
to histological observations, APCP- and saline-injeccted mice demonstrated similar numbers 173 
of apoptotic cells in the small intestines (43.8 ± 15.1 cells field of view-1, n = 3 and 42.2 ± 174 
15.5 cells field of view-1, n = 3, P = 0.9450) and skin (40.4 ± 11.3 cells field of view-1, n = 4 175 
and 25.8 ± 3.1 cells field of view-1, n = 4, P = 0.2576) (Fig 3e-f).  176 
APCP blockade increases serum hIL-2 concentrations in humanised mice 177 
An important part of GVHD development is the pro-inflammatory cytokine storm that drives 178 
immune cell proliferation and inflammatory damage2. Therefore, to determine if APCP 179 
altered cytokine production in humanised mice, serum hIL-2, hIL-6, hIL-10, hTNF-α and 180 
hIFN-γ concentrations from APCP- (n = 9) and saline-injected (n = 8) mice were analysed by 181 
a flow cytometric multiplex assay. APCP-injected mice demonstrated a significant increase in 182 
serum hIL-2 concentrations (3.2 ± 0.5 pg mL-1) compared to saline-injected mice (1.6 ± 0.3 183 
pg mL-1) (P = 0.0080) (Fig 4a). In contrast, APCP- and saline-injected mice demonstrated 184 
similar serum concentrations of hIL-6 (3.9 ± 1.5 pg mL-1, and 1.4 ± 0.7 pg mL-1, respectively, 185 
P = 0.1743) (Fig 4b), hIL-10 (22.2 ± 4.1 pg mL-1, and 19.1 ± 3.1 pg mL-1, respectively, P = 186 
0.7621) (Fig 4c), and TNF-α (21.3 ± 6.5 pg mL-1, and 16.6 ± 3.4 pg mL-1, respectively, P = 187 
0.7851) (Fig 4d). Serum hIFN-γ concentrations in both treatment groups exceeded the highest 188 
standard (>10,000 pg mL-1) and thus could not be compared (data not shown). Attempts to 189 
reassess serum hIFN-γ concentrations by ELISA were unsuccessful (results not shown), 190 
possibly due to freeze-thawing of serum.  191 
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To determine if APCP impacted hA2A or hP2X7 expression, mRNA expression of these 192 
molecules in the spleen was measured by qPCR. APCP- and saline-injected mice 193 
demonstrated similar relative mRNA expression of hA2A (0.22 ± 0.09 and 0.10 ± 0.03, 194 
respectively, P = 0.2863) (Fig 4e) and hP2X7 (1.0 ± 0.3 and 0.9 ± 0.3, respectively, P = 195 
0.8984) (Fig 4f). 196 
To confirm APCP does not impact P2X7 an ATP-induced YO-PRO-12+ uptake assay was 197 
performed. Freshly isolated hPBMCs were preincubated in the absence or presence of APCP 198 
or the P2X7 antagonist Brilliant Blue G (BBG), and ATP-induced YO-PRO-12+ uptake was 199 
assessed. ATP induced significant YO-PRO-12+ uptake into hCD3+ T cells, which was not 200 
affected by preincubation with APCP, but reduced by 99% by preincubation with BBG (P < 201 
0.005, n = 3) (Fig 4g). There was no significant difference in YO-PRO-12+ uptake between 202 
treatments in the absence of ATP (data not shown). 203 
Caffeine does not impact hPBMC engraftment in NSG mice 204 
The above data suggests that decreased adenosine and/or increased ATP production due to 205 
APCP-mediated blockade of CD39/CD73 worsens GVHD in humanised NSG mice. Thus, a 206 
role for ARs using the broad-spectrum AR antagonist, caffeine, in this process was examined 207 
using the same regime efficacious in an allogeneic mouse model of GVHD20. First, to 208 
determine if caffeine altered hPBMC engraftment, 3 weeks post-hPBMC injection blood cells 209 
from caffeine- (n = 13) and saline-injected (n = 15) mice were analysed by flow cytometry. 210 
Caffeine- and saline-injected mice demonstrated similar frequencies of human leukocytes 211 
(23.5 ± 3.5% and 28.5 ± 4.7%, respectively, P = 0.4135) (Fig 3a), which comprised T cells 212 
(92.5 ± 1.1% and 94.2 ± 0.7%, respectively, P = 0.1897) (Fig 3b), and non-B/T cells (7.5 ± 213 
1.1% and 5.8 ± 0.7%, respectively, P = 0.1897) (Fig 3c). 214 
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At end-point, splenocytes from caffeine- (n = 13) and saline-injected (n = 14) mice were 215 
analysed by flow cytometry. Caffeine- and saline-injected mice demonstrated similar 216 
frequencies of human leukocytes (72.2 ± 6.2% and 75.6 ± 3.8%, respectively, P = 0.6346) 217 
(Fig 3d). One caffeine-injected mouse revealed a human leukocyte frequency of only 11.2% 218 
(Fig 3d) but was included in subsequent analyses. Caffeine- and saline-injected mice 219 
demonstrated similar frequencies of human T cells (96.1 ± 1.0% and 93.7 ± 1.9%, 220 
respectively, P = 0.2934) (Fig 3e), which comprised hCD4+ T cells (51.7 ± 4.4% and 52.7 ± 221 
3.4%, respectively, P = 0.8658) and hCD8+ T cells (13.5 ± 2.3% and 18.5 ± 4.0%, 222 
respectively, P = 0.3011). Both caffeine- and saline-injected mice demonstrated greater 223 
frequencies of hCD4+ than hCD8+ T cells (P < 0.0001 and P < 0.0001, respectively) (Fig 3f). 224 
Caffeine- and saline injected mice demonstrated similar frequencies of CD4+ and CD8+ T cell 225 
subsets expressing CD39 and/or CD73 or neither of these molecules (Fig 3g, h; Table 3).  226 
Caffeine- and saline-injected mice also demonstrated similar frequencies of iNKT cells (3.1 ± 227 
0.9% and 1.6 ± 0.3%, respectively, P = 0.1088) (Fig 3i) and Treg cells (0.8 ± 0.1% and 0.9 ± 228 
0.2%, respectively, P = 0.8964) (Fig 3j). Caffeine- and saline-injected mice demonstrated 229 
similar frequencies of non-B/T cells (4.1 ± 1.1% and 5.8 ± 1.9%, respectively, P = 0.4381) 230 
(Fig 3k), which included similar frequencies of monocytes (0.2 ± 0.1%, n = 11 and 0.3 ± 231 
0.1%, n = 10 respectively, P = 0.5873) (Fig 3l) and DCs (0.6 ± 0.2%, n = 11 and 0.4 ± 0.2%, 232 
n = 10 respectively, P = 0.7984) (Fig 3m). 233 
Caffeine does not impact clinical or histological GVHD in humanised mice 234 
To determine if caffeine (AR blockade) impacted GVHD development, the above mice were 235 
monitored for disease development for up to 10 weeks. Caffeine- (n = 13) and saline-injected 236 
(n = 15) mice demonstrated similar weight loss (P = 0.7574) (Fig 4a) and clinical scores (P = 237 
0.0846) (Fig 4b) over 10 weeks. Moreover, caffeine- and saline-injected mice exhibited 238 
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similar MSTs (47 days and 45 days, respectively, P = 0.8741) and mortality over 10 weeks 239 
(87% and 87%, respectively, P = 1.000) (Fig 4c).  240 
Caffeine- and saline-injected mice demonstrated similar amounts of leukocyte infiltration and 241 
histological damage of the liver, small intestine and skin (Fig 4d). Moreover, the small 242 
intestines from mice from either group exhibited similar amounts of structural damage 243 
including enterocyte loss, crypt epithelial cell apoptosis and rounding of villi (Fig 2d). 244 
Similarly, skin from both caffeine- and saline-injected mice displayed mild basal epithelial 245 
cell apoptosis and epidermal thickening (Fig 2d). 246 
Caffeine does not impact serum cytokine concentrations in a humanised mouse model of 247 
GVHD 248 
Finally, to determine if caffeine altered cytokine production in humanised mice, serum hIL-2, 249 
hIL-6, hIL-10, hIFN-γ and hTNF-α concentrations were analysed as above. Caffeine- (n = 250 
12) and saline-injected (n = 11) mice demonstrated similar concentrations of serum hIL-2 251 
(1.5 ± 0.4 pg mL-1 and 1.0 ± 0.3 pg mL-1, respectively, P = 0.7556), hIL-6 (2.9 ± 1.3 pg mL-1 252 
and 3.7 ± 2.8 pg mL-1, respectively, P = 0.6577), and hIL-10 (23.0 ± 2.6 pg mL-1 and 26.8 ± 253 
6.4 pg mL-1, respectively, P = 0.8594). There was a trend of increased hTNF-α concentration 254 
in caffeine-injected mice, which approached but did not achieve statistical significance (18.6 255 
± 3.2 pg mL-1 and 13.7 ± 3.3 pg mL-1, respectively, P = 0.0852). Serum hIFN-γ 256 
concentrations in both treatment groups exceeded the highest standard (>10,000 pg mL-1) and 257 
thus could not be compared (data not shown). Attempts to reassess serum hIFN-γ 258 
concentrations by ELISA were unsuccessful (results not shown), possibly due to freeze-259 
thawing of serum. 260 
 261 
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DISCUSSION 262 
Accumulation of extracellular adenosine resulting from the CD39/CD73 pathway and 263 
subsequent activation of ARs is important in limiting disease in allogeneic mouse models of 264 
GVHD20,21. However, the role of this signalling axis in humanised mouse models of GVHD 265 
remained unknown. The current study demonstrated that CD39/CD73 blockade with APCP 266 
increases weight loss, liver GVHD and serum hIL-2 concentrations, and decreases the 267 
frequency of hCD39-hCD73-hCD4+ T cells in humanised mice. In contrast, blockade of ARs 268 
with caffeine did not impact clinical or histological GVHD or associated leukocytes or 269 
inflammatory markers. It is unlikely that caffeine failed to block ARs in the humanised mice, 270 
as this same caffeine regime augmented GVHD in allogeneic mice20 and caffeine impairs 271 
both murine and human ARs with similar efficacy28,29. Thus, the results of this study do not 272 
support a role for AR activation in limiting GVHD in humanised mice. Rather, this study 273 
supports a role for extracellular ATP in augmenting GVHD in this model. Blockade of CD39 274 
and/or CD73 with APCP maintains or increases extracellular ATP concentrations22,23. This 275 
ATP in turn may subsequently act on P2X7 and/or P2Y2 to promote GVHD in humanised 276 
mice. These P2 receptors are involved in GVHD progression in humanised15,16 and/or 277 
allogeneic models12-14,17 of this disease, although the role of P2Y2 in the former remains to be 278 
elucidated. Furthermore, given that APCP did not alter mortality or histological 279 
gastrointestinal tract or cutaneous GVHD in humanised mice, the impact of this compound on 280 
extracellular ATP concentrations and subsequent P2X7 and/or P2Y2 activation my be 281 
limited.  282 
The current study demonstrates that CD39/CD73 blockade with APCP augments liver 283 
GVHD, including increased leukocyte infiltration, human T cell infiltration and apoptosis in 284 
humanised mice. This finding is similar to the increased liver GVHD in CD73 deficient mice 285 
compared to wild-type mice in allogenic GVHD20,21. The inability of AR blockade with 286 
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caffeine to augment liver GVHD in humanised mice supports the concept that extracellular 287 
ATP rather than adenosine contributes to liver GVHD in humanised mice. In support of this, 288 
ATP activation of P2X7 worsens liver GVHD in an allogeneic mouse model12, and 289 
pharmacological blockade of P2X7 reduces liver GVHD in both allogeneic12,14 and 290 
humanised15,16 mouse models of this disease. Moreover, two of these studies 14,16 indicate that 291 
the liver may be particularly sensitive to P2X7-mediated damage in both allogeneic and 292 
humanised mice. 293 
The current study also demonstrated the presence of serum hIL-2, hIL-6, hIL-10, hTNF-α and 294 
hIFN-γ in humanised mice with GVHD, and implicates a pro-inflammatory role for hIL-2 in 295 
GVHD development in this model. Presumably this cytokine is acting on donor human 296 
effector T cells as host murine leukocytes in NSG mice do not express functional IL-2 297 
receptors due to the absence of the IL-2 receptor γ chain30 and since either donor human 298 
CD4+ or CD8+ T cells are sufficient to mediate GVHD in humanised NSG mice31-33. 299 
Consistent with this, administration of low dose IL-2 in allogeneic and humanised mouse 300 
models of GVHD results in the activation of donor effector T cells34,35, which circumvent any 301 
potential clinical benefits imparted by the expanded Treg cell population in these mice35. 302 
Notably, co-administration of IL-10 with IL-2 can limit the expansion of effector T cells and 303 
increase survival in humanised mice with GVHD34. However in the current study, hIL-10 304 
concentrations where similar in APCP- and saline-injected mice suggesting that any potential 305 
effects of hIL-10 on hIL-2 was the same between treatments. Finally, in the current study, 306 
serum concentrations of hIL-2, hIL-6, hIL-10 and hTNF-α were in the pg mL-1 range, which 307 
contrasted the 1000-fold greater amounts of serum hIFN-γ. Thus, this suggests hIFN-γ may 308 
have a major role in disease development in this humanised mouse model of GVHD. 309 
Consistent with this, P2X7 blockade in this model reduced histological GVHD, which 310 
coincided with reduced concentrations of serum hIFN-γ15. 311 
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The current study demonstrated that APCP but not caffeine decreases human 312 
CD39-CD73-CD4+, but not CD39-CD73-CD8+ T cells. The reduced frequency of human 313 
CD39-CD73-CD4+ T cells due to APCP treatment may be due a compensatory mechanism 314 
that involves upregulating CD39 and/or CD73 to increase ATP degradation and promote 315 
adenosine generation. This is supported by the trend of increased frequencies of human 316 
CD39+CD73-CD4+ and CD39-CD73+CD4+ T cells following APCP treatment. However, 317 
these increases were not statistically significant and there was no increased trend in human 318 
CD39+CD73+CD4+ T cells in these mice. Thus, the reason for the reduced frequency of 319 
human CD39-CD73-CD4+ T cells following APCP treatment in vivo requires further 320 
elucidation.  321 
The current study confirms that NSG mice injected with hPBMCS engraft hCD4+ and hCD8+ 322 
T cells as well as Tregs, but shows for the first time that humanised NSG mice also engraft 323 
human iNKT cells. This engraftment of human iNKT cells suggests that this model could be 324 
used to study these cells in vivo and allow manipulation of these cell types to alter disease 325 
outcomes. In allogeneic mouse models of GVHD, both host36 and donor37 iNKT cells can 326 
attenuate disease, whilst adoptive transfer of these cells can prevent GVHD in such models38.  327 
The current study also demonstrates that humanised NSG mice engraft human monocytes and 328 
DCs. Previous studies have shown that NSG mice engraft human monocytes and DCs when 329 
injected with human cord blood39, and engraft human monocytes when injected with 330 
hPBMCs40,41. Similarly, SCID mice injected with hPBMCs engraft human DCs42, but the 331 
current study is the first to demonstrate DC engraftment in NSG mice injected with hPBMCs. 332 
Human T cells recognise murine major histocompatibility complex I and II molecules in 333 
NSG mice to cause GVHD27, but the identity of the APCs involved remains to be determined. 334 
However it is known that both host and donor APCs are involved in GVHD development in 335 
allogeneic mouse models of this disease43,44. The engraftment of human monocytes and DCs 336 
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in NSG mice suggests that human T cells may at least in part be activated by human antigen 337 
presenting cells in this model. A large proprotion of the non-B/T cell population remain 338 
unidentified, but may represent NK cells, which can be present in humanised NSG mice16. 339 
Finally, it should be noted that a limitation of this study was that proportions and not absolute 340 
numbers of each subset were determined. 341 
In conclusion, CD39/CD73 blockade with APCP, but not AR blockade with caffeine, 342 
augmented GVHD in humanised mice. These results support the known roles of extracellular 343 
ATP in promoting GVHD but do not support evidence that extracellular adenosine can limit 344 
GVHD in this humanised model. This data provides further support for P2X7 blockade as a 345 
therapeutic approach to prevent GVHD in humans, but does not exclude the use of A2A 346 
activation as an alternate or additional therapeutic approach to prevent GVHD in humans. 347 
 348 
METHODS 349 
Humanised mouse model of GVHD 350 
Experiments involving human blood and mice were approved by the respective Human and 351 
Animal Ethics Committees (University of Wollongong, Wollongong, Australia). A 352 
humanised mouse model of GVHD was used as described24 using human blood from two 353 
male and one female healthy adult donors. Briefly, hPBMCs, isolated by  density 354 
centrifugation using Ficoll-Paque PLUS (GE Healthcare; Uppsala, Sweden), were injected 355 
intra-peritoneally (i.p.) (10 x 106 hPBMCs mouse-1) into female NSG mice aged 5-7 weeks 356 
(Australian BioResources; Moss Vale, Australia). For CD73 blockade, humanised mice were 357 
injected i.p. daily with APCP (Sigma-Aldrich; St Louis, MO, USA) (50 mg kg-1) or saline 2 358 
hours following hPBMC injection and then daily over the next 6 days20. For AR blockade, 359 
mice were injected i.p. daily with caffeine (Sigma-Aldrich) (10 mg kg-1) or saline 2 hours 360 
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following hPBMC injection and then daily for the next 13 days20. At 3 weeks post-hPBMC 361 
injection, mice were checked for engraftment by immunophenotyping of tail vein blood. 362 
Mice were monitored for signs of GVHD using a scoring system, giving a total clinical score 363 
out of 10 (Table 1), as described15. Mice were euthanized at 10 weeks post-injection of 364 
hPBMCs, or earlier if exhibiting a clinical score of ≥ 8 or a weight loss of ≥ 10%, according 365 
to the approved animal ethics protocol.  366 
Immunophenotyping by flow cytometry 367 
Tail vein blood (week 3) and spleen cells (end-point) were obtained from mice and lysed with 368 
ammonium chloride potassium buffer and immunophenotyped as described15 using the 369 
antibodies listed in Table S1 and the gating strategy depicted in the Supplementary Figures 370 
S1 and S2. Data was collected using a BD (San Jose, CA, USA) Fortessa-X20 Flow 371 
Cytometer (using band pass filters 450/50 for BV421, 710/50 for BV711, 525/50 for FITC, 372 
586/15 for PE, 695/40 for PerCP-Cy5.5, 780/60 for PE-Cy7 and 670/30 for APC). The 373 
relative percentages of cells were analyzed using FlowJo software v8.7.1 (TreeStar Inc.; 374 
Ashland, OR, USA) (Fig S1 and S2).  375 
Histological analysis 376 
Formalin-fixed tissue sections (5 μm) were stained with haematoxylin and eosin (POCD; 377 
Artarmon, Australia) and histology assessed as described15. Total numbers of leukocytes in 378 
GVHD target organs were quantified from captured images (Leica DMRB microscope, 379 
Wetzlar, Germany) using FIJI is just ImageJ (FIJI) software45.  380 
Immunohistochemical analysis 381 
To identify human T cells, formalin-fixed tissue sections (5 μm) were deparrifinised, and 382 
stained with rabbit anti-hCD3 mAb (clone EP449E) (Abcam, Cambridge, UK) and 383 
counterstained with haematoxylin as described15. To identify apoptotic cells, an in-situ 384 
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Apoptosis Detection Kit (Abcam) was used as per the manufacturer’s instructions. 385 
Immunohistochemistry images were captured using a Leica DMRB microscope. Total 386 
numbers of hCD3+ T cell infiltrates in livers and apoptotic cells in liver, skin and small 387 
intestine were quantified from captured images using FIJI is just ImageJ (FIJI) software45. 388 
Cytokine analysis by a flow cytometric multiplex assay 389 
Serum was obtained from mice at end-point as described15 and cytokine concentrations were 390 
measured using a human Th1 LEGENDPlex kit (BioLegend; San Diego, CA, USA) as per 391 
the manufacturer’s instructions. IFN-γ measurements were reattempted on previously freeze-392 
thawed serum using the Ready-Set-GO! ELISA kit (Thermo Fisher Scientific) as per 393 
manufacturer’s instructions. 394 
RNA isolation and cDNA synthesis 395 
Tissues removed from euthanized mice were stored in RNAlater (Sigma-Aldrich) at -20°C 396 
until required. RNA was isolated using TRIsure reagent (Bioline, London, UK), as per the 397 
manufacturer’s instructions. Isolated RNA was converted immediately to cDNA using the 398 
qScript cDNA Synthesis Kit (Quanta Biosciences, Beverly, MA, USA), as per the 399 
manufacturer’s instructions, and stored at -20°C. cDNA was checked by polymerase chain 400 
reaction (PCR) amplification of the housekeeping gene glyceraldehyde 3-phosphate 401 
dehydrogenase (Invitrogen, Carlsbad, CA, USA) for 35 cycles (95°C for 1 min, 55°C for 1 402 
min and 72°C for 1 min) and a holding temperature of 48C. Purity and size of amplicons 403 
were confirmed by 2% agarose gel electrophoresis. 404 
Quantitative real-time PCR 405 
Quantitative real-time PCR (qPCR) was performed using TaqMan Universal Master Mix II 406 
(Thermo Fisher Scientific, Waltham, MA, USA), according to the manufacturer’s 407 
instructions, with primers for FAM-labelled human hypoxanthine phosphoribosyl transferase 408 
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1 (Hs99999909_m1) and hADORA2A (Hs00948727_g1), and VIC-labelled hP2X7(B) 409 
(AIOIXC2) (Thermo Fisher Scientific), as indicated. qPCR cycles consisted of two initial 410 
steps of 50°C for 2 min and 95°C for 10 min and 40 cycles of 95°C for 15 s and 60°C for 1 411 
min. qPCR was conducted in triplicate, and were performed on a QuantStudio 5 (Thermo 412 
Fisher Scientific), and analysis was conducted using QuantStudio Design and Analysis 413 
software version 1.4.1. 414 
ATP-induced YO-PRO-12+ uptake assay 415 
P2X7 pore formation was quantified by measuring ATP-induced YO-PRO-12+ uptake, as 416 
described previously15. Briefly, freshly isolated hPBMCs in NaCl medium (145 mM NaCl, 5 417 
mM KCl, 5 mM glucose and 10 mM HEPES, pH 7.4) were incubated in the absence or 418 
presence of 2 μM APCP46 or 10 μM BBG47 (Sigma-Aldrich) for 15 min at 37°C, and then 419 
incubated with 1 μM YO-PRO-1 iodide (Molecular Probes, Eugene, OR, USA) in the 420 
absence or presence of 1 mM ATP (Sigma-Aldrich) for 5 min. Incubations were stopped by 421 
addition of ice-cold NaCl medium containing 20 mM MgCl2 (MgCl2 medium) and 422 
centrifugation (300 g for 3 min). Cells were incubated with BV711-conjugated anti-hCD3 423 
mAb for 10 min and washed with NaCl medium. Data were collected using an LSRFortessa 424 
X-20 Flow Cytometer (band-pass filter 525/50 for YO-PRO-12+ and 710/50 for BV711) and 425 
FACSDiva software version 8.0. The mean fluorescence intensity of YO-PRO-12+ was 426 
determined using FlowJo software v8.7.1. 427 
Statistical Analysis 428 
Data are given as mean ± standard error of the mean (SEM). Statistical differences were 429 
calculated using Student’s t-test for single comparisons or one-way analysis of variance 430 
(ANOVA) with Tukey’s post-hoc test for multiple comparisons. Student’s t-tests were two-431 
tailed except for immunohistochemistry (one-tailed) where each a priori hypothesis was 432 
based on intial histology findings. Weight and clinical score were analysed using a repeated 433 
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measures two-way ANOVA. Survival (MST) was compared using the log-rank (Mantel-Cox) 434 
test. Mortality was compared using Fisher’s exact test. All statistical analyses and graphs 435 
were generated using GraphPad Prism 5 for PC (GraphPad Software; La Jolla, CA, USA). P 436 
< 0.05 was considered significant for all tests. 437 
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 583 
FIGURE LEGENDS 584 
Figure 1. APCP reduces human CD4+CD39-CD73- cells but not other T cell subsets in a 585 
humanised mouse model of GVHD 586 
(a-m) The percentage of human leukocytes in (a-c) blood at 3 weeks post-hPBMC injection 587 
and (d-m) spleens at end-point from humanised NSG mice injected with saline (control) or 588 
the CD39/CD73 inhibitor APCP (50 mg/kg) were determined by flow cytometry. (a, d) 589 
hCD45+ leukocytes are expressed as a percentage of total (mCD45+ and hCD45+) leukocytes. 590 
(b, e) T cells (hCD3+hCD19-) and (c, k) non-B/T cells (hCD3-hCD19-) are expressed as a 591 
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percentage of hCD45+ leukocytes. (f) hCD4+ and hCD8+ T cell subsets are expressed as a 592 
percentage of hCD3+ leukocytes. ** P < 0.005, *** P < 0.0001 compared to hCD8+ T cells. 593 
(g-h) The expression of hCD39 and hCD73 was analysed on (g) hCD4+ and (h) hCD8+ T cell 594 
subsets. * P < 0.05 compared to respective saline control. (i) iNKT cells (hVα24-Jα18+) are 595 
expressed as a percentage of hCD3+hCD19- T cells and (j) Treg cells (hCD25+hCD127lo) are 596 
expressed as a percentage of hCD3+hCD4+ T cells. (l) monocytes (hCD14+CD83-) and (m) 597 
DCs (hCD14-CD83+) are expressed as a percentage of non-B/T cells. (a-m) Data represents 598 
group means ± SEM; symbols represent individual mice (saline n = 9, APCP n = 8-9) from 599 
two independent experiments.  600 
Figure 2. CD73 blockade worsens weight loss in a humanised mouse model of GVHD 601 
(a-c) Humanised NSG mice injected with saline (control) or the CD39/CD73 inhibitor APCP 602 
(50 mg/kg) were monitored for (a) weight loss, (b) clinical score and (c) survival over 10 603 
weeks. * P < 0.05 compared to saline-injected mice. Data represents (a-b) group means ± 604 
SEM or (c) percent survival (saline n = 9, APCP n = 9) from two independent experiments.  605 
Figure 3. CD73 blockade augments liver histology in a humanised mouse model of 606 
GVHD 607 
(a-f) Liver, small intestine and skin, collected at end-point, were sectioned and stained with 608 
(a) haematoxylin and eosin, (c) anti-hCD3 monoclonal antibody with DAB detection system 609 
and haematoxylin or (e) TUNEL with DAB detection system and methyl green. Images were 610 
captured by microscopy, and (b) leukocyte and (d) human T cell infiltration, and (f) apoptosis 611 
quantified using FIJI. Each image is representative of eight mice per group for histology, or 612 
four mice per goup for IHC from two independent experiments; (a, c, e) bar represents 100 613 
μm. * P < 0.05 compared to respective saline control. (b, f) data represents group means ± 614 
SEM; symbols represent individual mice; * P < 0.05 compared to respective saline control. 615 
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Figure 4. CD73 blockade increases serum hIL-2 concentrations but does not affect A2A 616 
or P2X7 expression in a humanised mouse model of GVHD 617 
(a-d) Serum was collected at end-point. Concentrations of serum human (a) IL-2, (b) IL-6, 618 
(c) IL-10 and (d) TNF-α were analysed using a flow cytometric multiplex assay. * P < 0.05 619 
compared to respective saline control. Data represents group means ± SEM (saline n = 8, 620 
APCP n = 9) from two independent experiments. (e-f) Spleens were collected at end-point. 621 
The relative expression of (e) hA2A and (f) hP2X7 were examined by qPCR. Data represent 622 
group mean ± SEM; symbols represent individual mice (saline n = 7, APCP n = 7) from two 623 
independent experiments. (g) Freshly isolated hPBMCs were pre-incubated for 15 min in the 624 
absence or presence of 2 μM APCP or 10 μM BBG and then with 1 μM YO-PRO-12+ in the 625 
absence or presence of 1 mM ATP for 5 min at 37 °C. Assays were stopped by addition of 626 
MgCl2 medium and centrifugation. Cells were then labelled with BV711-conjugated hCD3 627 
mAb. YO-PRO-12+ uptake into hCD3+ T cells was assessed by flow cytometry. ** P < 0.005 628 
compared to control. Data represents group means ± SEM (n = 3 donors) from one 629 
experiment. 630 
Figure 5. Caffeine does not impact human leukocyte engraftment in a humanised mouse 631 
model of GVHD 632 
(a-m) The percentage of human leukocytes in (a-c) blood at 3 weeks post-hPBMC injection 633 
and (d-m) spleens at end-point from humanised NSG mice injected with saline (control) or 634 
the AR antagonist caffeine (10 mg/kg) were determined by flow cytometry. (a, d) hCD45+ 635 
leukocytes are expressed as a percentage of total (mCD45+ and hCD45+) leukocytes. (b, e) T 636 
cells (hCD3+hCD19-) and (c, k) non-B/T cells (hCD3-hCD19-) are expressed as a percentage 637 
of hCD45+ leukocytes. (f) hCD4+ and hCD8+ T cell subsets are expressed as a percentage of 638 
hCD3+ leukocytes. *** P < 0.0001 compared to hCD8+ T cells. (g, h) The expression of 639 
hCD39 and hCD73 was analysed on (g) hCD4+ and (h) hCD8+ T cell subsets. i iNKT cells 640 
(hVα24-Jα18+) are expressed as a percentage of hCD3+hCD19- T cells and (j) Treg cells 641 
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(hCD25+hCD127lo) are expressed as a percentage of hCD3+ hCD4+ T cells. (l) monocytes 642 
(hCD14+CD83-) and (m) DCs (hCD14-CD83+) are expressed as a percentage of non-B/T 643 
cells. (a-m) Data represents group means ± SEM; symbols represent individual mice (saline n 644 
= 15, caffeine n = 13) from three independent experiments.   645 
Figure 6. Caffeine does not impact disease in a humanised mouse model of GVHD 646 
(a-h) Humanised NSG mice injected with saline (control) or the AR antagonist caffeine (10 647 
mg/kg) were monitored for (a) weight loss, (b) clinical score, and (c) survival over 10 weeks. 648 
Data represents (a-b) group means ± SEM or (c) percent survival (saline n = 9, caffeine n = 649 
9). (d-h) Tissues and serum were collected at end-point. (d) Liver, small intestine and skin 650 
were sectioned and stained with haematoxylin and eosin and images were captured by 651 
microscopy, with each image representative of 13 mice per group; bar represents 100 μm. (e-652 
h) Concentrations of serum human (e) IL-2, (f) IL-6, (g) IL-10 and (h) TNF-α were analysed 653 
using a flow cytometric multiplex assay. Data represents group means ± SEM (saline n = 15, 654 
caffeine n = 13) from three independent experiments. 655 
 656 
SUPPLEMENTARY FIGURES 657 
Fig. S1. Flow cytometric gating of leukocytes in blood from humanised mice  658 
The percentage of human leukocytes in blood at 3 weeks post-hPBMC injection collected 659 
from all humanised NSG mice were determined by flow cytometry. Forward scatter area 660 
(FSC-A) and forward scatter height (FSC-H) were used to identify single cells (far left 661 
panel). Forward scatter (FSC-A) and side scatter (SSC-A) (middle left panel) were used to 662 
identify and subsequently analyse the percentages of human leukocytes (hCD45+mCD45-; 663 
middle right panel), which comprised T and non-B/T cells (hCD3+hCD19- and 664 
hCD3-hCD19- respectively; far right panel).  665 
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Fig. S2. Flow cytometric gating of leukocytes in spleens from humanised mice  666 
(a-b) The percentage of human leukocytes in spleens at end-point collected from all 667 
humanised NSG mice were determined by flow cytometry. (a) Forward scatter (FSC-A, FSC-668 
H) and side scatter (SSC-A) were used to identify and subsequently analyse single leukocytes 669 
(top left and middle panels). These leukocytes were analysed to determine the percentages of 670 
human leukocytes (hCD45+mCD45-; top right panel), and subsequently used to identify T 671 
cells (hCD3+hCD19-; bottom left panel) and iNKT cells (hCD3+hCD19-hVα24-Jα18+; bottom 672 
middle panel), or non-B/T cells (hCD3-hCD19-; bottom left panel), which were subsequently 673 
used to identify monocytes and DCs (hCD14+CD83- and hCD14-CD83+ respectively; bottom 674 
right panel). (b) Single leukocytes were gated as above. T cells were identified (hCD3+; top 675 
left panel), and subsequently used to determine hCD4+ and hCD8+ T cell subsets (top middle 676 
panel), and hCD39 and hCD73 expression on hCD4+ (top right panel) and hCD8+ (bottom 677 
left panel) T cells was analysed. hCD4+ T cells were also gated to identify Tregs 678 
(hCD25+hCD127lo; bottom right panel). 679 
Fig. S3. Flow cytometric gating for ATP-induced YO-PRO-12+ uptake into human T 680 
cells 681 
ATP-induced YO-PRO-12+ uptake into freshly isolated hPBMCs was determined by flow 682 
cytometry. Forward scatter (FSC-A, FSC-H) and side scatter (SSC-A) were used to identify 683 
and subsequently analyse single leukocytes (left and middle panels). BV711-conjugated 684 
hCD3 was then used to identify and analyse T cells (right panel). 685 
TABLE 686 
Table 1. Clinical scoring of GVHD in humanised NSG mice. 687 
GRADE 0 1 2 
Weight loss < 5% 5% to 10% > 10% 
Posture Normal Hunching noted only at rest Severe hunching 
Activity Normal Mild to moderately decreased Stationary unless stimulated 
Fur texture Normal Mild to moderate ruffling Severe ruffling poor grooming 
Skin Integrity Normal Scaling of paws/tail Obvious areas of involved skin 
Mice with a total score of 8 or more were euthanized that same day. 688 
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 689 
Table 2. APCP reduces human CD4+CD39-CD73- T cells in a humanised mouse model 690 
of GVHD. 691 
T cell subset hCD39 and hCD73 
Expression 
Saline APCP P-value 
hCD4+ CD39+CD73- 5.5 ± 2.1% 10.2 ± 4.1% 0.3441 
 CD39-CD73+ 3.7 ± 0.9% 13.1 ± 5.5% 0.1347 
 CD39+CD73+ 0.8 ± 0.4% 1.3 ± 0.4% 0.4247 
 CD39-CD73- 89.9 ± 2.4% 75.4 ± 5.8% 0.0441* 
hCD8+ CD39+CD73- 36.4 ± 5.0% 41.4 ± 3.0% 0.3867 
 CD39-CD73+ 2.8 ± 0.6% 3.8 ± 1.0% 0.4342 
 CD39+CD73+ 4.1 ± 1.2% 5.5 ± 1.6% 0.5035 
 CD39-CD73- 56.7 ± 5.8% 49.3 ± 4.6% 0.3247 
All data obtained from Figure 1g-h. * P < 0.05 compared to respective saline control. 692 
Table 3. Caffeine does not impact human CD39+/-CD73+/- T cells in a humanised mouse 693 
model of GVHD. 694 
T cell subset hCD39 and hCD73 
Expression 
Saline Caffeine P-value 
hCD4+ CD39+CD73- 11.0 ± 3.6% 14.2 ± 4.6% 0.5926 
 CD39-CD73+ 5.3 ± 1.9% 3.2 ± 1.0% 0.3572 
 CD39+CD73+ 0.7 ± 0.3% 0.8 ± 0.2% 0.9430 
 CD39-CD73- 83.0 ± 3.5% 81.8 ± 4.4% 0.8425 
hCD8+ CD39+CD73- 39.5 ± 5.4% 33.3 ± 6.2% 0.4544 
 CD39-CD73+ 5.9 ± 2.8% 3.3 ± 0.7% 0.3922 
 CD39+CD73+ 5.2 ± 2.0% 4.9 ± 1.4% 0.9055 
 CD39-CD73- 50.6 ± 6.0% 57.4 ± 6.9% 0.4627 
All data obtained from Figure 5g-h. 695 
 696 
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SUPPLEMENTARY TABLE 697 
Table S1. Monoclonal antibodies used for flow cytometry. 698 
Target Fluorochrome Clone* 
CD14 BV421 MϕP9 
CD127 BV421 HIL-7R-M21 
CD3 BV711 UCHT1 
CD45 FITC HI30 
CD8 FITC RPA-T8 
CD25 PE M-A251 
CD3 PE UCHT1 
CD83 PE HB15e 
CD4 PerCP-Cy5.5 L200 
CD45 PerCP-Cy5.5 30-F11 
CD73 PE-Cy7 AD2 
Vα24-Jα14 PE-Cy7 6B11 
CD19 APC HIB19 
CD39 APC TU66 
*All antibodes mouse anti-human except clone 30-F11 (rat anti-mouse); all antibodies from BD 699 
Biosciences except clone 6B11 (BioLegend). 700 
701 
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